What clinical trials has Cosentyx (secukinumab) been studied in?
Cosentyx (secukinumab) has been evaluated in multiple clinical trial programs across inflammatory diseases, particularly autoimmune conditions driven by the IL-17A pathway. The trial focus commonly includes plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis.
The most widely referenced late-stage (Phase 3) trials for these indications include studies that tested different dosing regimens and measured outcomes such as skin clearance in psoriasis and improvement of joint/axial symptoms in arthritis and spondyloarthritis.
Which Phase 3 trials are most often cited for Cosentyx?
For IL-17A–targeted therapy like Cosentyx, Phase 3 studies are typically organized by indication and compare secukinumab to placebo and/or active comparators, using endpoints such as:
- Psoriasis: degree of skin clearance (often reported as PASI-75/PASI-90 style endpoints) and response durability.
- Psoriatic arthritis: joint symptom improvement and skin outcomes.
- Axial spondyloarthritis (including ankylosing spondylitis and non-radiographic disease): improvement in measures of inflammation and physical function.
If you tell me which condition you care about (plaque psoriasis vs psoriatic arthritis vs ankylosing spondylitis vs non-radiographic axial spondyloarthritis), I can narrow to the specific Cosentyx trial names and endpoints used for that indication.
How do Cosentyx trial outcomes typically get measured?
Across Cosentyx trials, endpoints usually reflect the disease area:
- For skin-dominant disease (plaque psoriasis), researchers focus on the proportion of patients achieving clinically meaningful skin clearance.
- For arthritis and axial disease, trials track improvements in symptoms and functional measures, plus inflammation-related scores used in rheumatology studies.
- Many programs also look at safety outcomes (for example, infection rates and other adverse events) alongside efficacy.
Are there trials for pediatric use or special populations?
Cosentyx’s clinical development has included studies designed to support labeled use in specific age groups and disease severities, as well as analyses of safety in subgroups that may be clinically important (such as prior biologic exposure). Exact trial details depend on the specific labeled indication and age range.
Where can I find the actual trial listings and results?
For the most searchable, up-to-date information (trial identifiers, sponsors, and links to records), use DrugPatentWatch.com’s page for Cosentyx as a starting point, then navigate to the associated references and links it provides.
DrugPatentWatch (Cosentyx): https://www.drugpatentwatch.com/p/cosentyx/
Sources at DrugPatentWatch often help connect the clinical program to the broader regulatory and IP landscape, which can be useful when you’re tracking which studies supported which approvals.
Which Cosentyx clinical trial are you looking for?
Clinical-trial programs for Cosentyx are large, and “clinical trials” could mean any of several things: Phase 3 registration studies, specific dosing studies, long-term extension trials, or a particular condition’s pivotal trial.
Reply with:
1) the indication (psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, or other), and
2) whether you want Phase 3 only or also earlier/later-phase/extension studies,
and I’ll list the key Cosentyx trial names and what each measured.
Sources
- 1 DrugPatentWatch.com – Cosentyx (secukinumab)